Acrivon Therapeutics reported positive Phase 2 clinical data for ACR-368 in endometrial cancer, showing a 62.5% response rate, and announced FDA clearance for ACR-2316 with first dosing expected in Q4 2024, while confirming $220.4 million in cash to fund operations until mid-2026.